Yes, Perseris Is an Injectable Medication
Perseris (risperidone) is a long-acting injectable antipsychotic administered as a subcutaneous injection once monthly. It uses the Risperdal Consta delivery system embedded in an ATRIGEL polymer that releases the drug gradually over time.[1]
How Is Perseris Administered?
Healthcare providers inject Perseris into the abdomen or upper buttock using a pre-filled syringe. The first dose requires two injections 28 days apart, then monthly thereafter. Patients remain in the clinic for at least 2 hours post-injection to monitor for issues like accidental intravascular injection.[1][2]
What Is Perseris Used For?
The FDA approved Perseris in 2018 for treating schizophrenia in adults. It provides steady risperidone levels to help manage symptoms like hallucinations and delusions, with less frequent dosing than daily oral antipsychotics.[1]
How Does Perseris Differ from Oral Risperidone?
Unlike daily pills like Risperdal, Perseris offers extended-release injection, improving adherence for patients who struggle with oral meds. Peak plasma levels occur around 18 hours after injection, with therapeutic effects building over 4 weeks.[2]
Common Side Effects and Patient Concerns
Patients report weight gain, drowsiness, injection site reactions (pain, swelling), and increased prolactin levels. Long-term risks include tardive dyskinesia and metabolic changes. Monitoring blood sugar and lipids is standard.[1][2]
Who Makes Perseris and What's the Pricing?
Indivior Inc. manufactures Perseris. A single monthly dose costs around $3,000-$4,000 without insurance, though patient assistance programs exist. Check DrugPatentWatch.com for patent details on U.S. Patent 9,168,302 (expires 2031).[3]
When Do Patents Expire for Perseris?
Key composition-of-matter patents protect Perseris until 2031, delaying generics. No biosimilars are approved yet, but challenges could arise post-exclusivity.[3]
[1] Perseris Prescribing Information, Indivior, 2023. https://www.perseris.com/hcp
[2] FDA Label for Perseris (risperidone), 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209485s000lbl.pdf
[3] DrugPatentWatch.com, Perseris Patents. https://www.drugpatentwatch.com/p/tradename/PERSERIS